California Department of Insurance
Mental Health Parity Supporting Documentation 2019 – Instructions
-3-
a. the quantitative analysis is based on the total allowed amounts (not limited to the portion paid
by the plan), projected for the applicable plan year; 45 C.F.R. § 146.136(c)(3)(i)(C); 78 Fed. Reg.
68,240, 68,243 (Nov. 13, 2013);
b. the quantitative analysis for each classification and sub-classification accounts for all expected
payments for all covered medical/surgical benefits under the plan; § 146.136(c)(3)(i)(C); and
c. a “reasonable method” was used to determine the expected payment amounts.
§ 146.136(c)(3)(i)(E). Please ensure that the data used to project total plan payments for each
plan’s quantitative analysis complies with the requirements described in recent federal
guidance, as follows:
Basing the analysis on an issuer’s entire overall book of business expected or book of
business in a specific region or State is not a reasonable method to determine the
dollar amount of all plan payments under MHPAEA. ACA FAQ 31, Q8 (Apr. 20, 2016).
For small group and individual market plans, an issuer must consider “plan”-level (as
opposed to the “product”-level) claims data to perform the substantially all and
predominant analyses, as such terms are defined in 45 C.F.R. § 144.103, and must rely
on such data if it is credible to perform the required projections. ACA FAQ 34, Q3 (Oct.
27, 2106).
If an actuary who is subject to and meets the qualification standards for the issuance of
a statement of actuarial opinion in regard to health plans in the United States,
including having the necessary education and experience to provide the actuarial
opinion, determines that a group health plan or issuer does not have sufficient data at
the plan or product level for a reasonable projection of future claims costs for the
substantially all or predominant analyses, the issuer should utilize other reasonable
claims data to make a reasonable projection to conduct actuarially-appropriate
analyses. Data from other similarly-structured products or plans with similar
demographics may be utilized for the analyses if actuarially appropriate. In addition, to
the extent possible, the claims data should be customized to reflect the characteristics
of the group health plan to which the substantially all and predominant analyses are
being applied. As part of using a “reasonable method” to make these projections, plans
and issuers should document the assumptions used in choosing a data set and making
projections. ACA FAQ 34, Q3 (Oct. 27, 2106).
Accordingly, as part of component (1)(c), please clearly describe the following, in addition to any
other relevant information:
i. The source of the claims data used to determine the expected payment amounts for
each plan’s analysis. Please identify the specific plan(s) or product(s) from which the
data was sourced.
ii. The time period of the claims data—e.g., calendar years 2016 and 2017.
iii. What adjustments, if any, were made to the data or payment projections.
iv. NOTE: If data other than plan-level data was used for each plan’s analysis, please
submit a separate actuarial certification addressing: (1) the sufficiency and
credibility of plan-level and product-level data; and (2) why the substitute dataset
used for the analyses is reasonable and actuarially appropriate, including a
description of any assumptions used in choosing the data and making projections.
2. A description of the methodology used to perform the quantitative mental health parity analysis of
each cost sharing type.